Article

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus Immunotherapeutic

2022-01-06

Abstract excerpt

Intravenous administration (IV) of antiviral monoclonal antibodies (mAbs) is challenging due to limited resources for performing infusions during an ongoing epidemic. An ebolavirus therapeutic administered via intramuscular (IM) injection would reduce these burdens and allow rapid treatment of exposed individuals during an outbreak. Here, we demonstrate how MBP134, a two mAb pan-ebolavirus cocktail, reverses the c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 57b56187-df63-5a0d-b7af-e3ce0159980c
DOI: 10.1101/2022.01.06.475142

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus ImmunotherapeuticDOI 10.1101/2022.01.06.475142Read

Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protectionSemantic proximity Read

Monoclonal antibodies for the treatment of Ebola virus disease.Semantic proximity Read

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsSemantic proximity Read

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Zaire ebolavirus, Sudan ebolavirus, Marburg and Lassa virusesSemantic proximity Read

Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.Semantic proximity Read

A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virusSemantic proximity Read

Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membraneSemantic proximity Read

Monotherapy with antibody 1C3 partially protects Ebola virus-exposed macaques.Semantic proximity Read

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challengeSemantic proximity Read

Early insights into viability of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreakSemantic proximity Read

Pathogenesis and natural history of the Bundibugyo species of <i>Orthoebolavirus</i> in nonhuman primatesSemantic proximity Read

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse ModelSemantic proximity Read